Quick Answer
Onconetix, Inc. reported R&D Expense of $154.4 thousand for fiscal year 2024.
Onconetix, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $154.4K | -92.1% |
| 2023 | $1.95M | -52.8% |
| 2022 | $4.13M | +211.7% |
| 2021 | $1.33M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $24.5K | -50.1% | -77.6% |
| September 30, 2024 | $109.4K | -50.1% | +123.4% |
| March 31, 2024 | $49.0K | -95.5% | -77.7% |
| September 30, 2023 | $219.2K | -81.3% | -74.1% |
| June 30, 2023 | $846.9K | -34.5% | -21.7% |
| March 31, 2023 | $1.08M | +137.8% | -7.9% |
| September 30, 2022 | $1.18M | +335.5% | -9.1% |
| June 30, 2022 | $1.29M | +144.3% | +184.2% |
- Onconetix, Inc. showed a decrease of -92.1% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2024 period, Onconetix, Inc.’s r&d expense has declined by 88.4% (from $1.33 million to $154.4 thousand).
- The most recent figure is from Onconetix, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 2, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: